Success Metrics

Completion Rate
0%(0/1)
Active Trials
3(75%)
Terminated
1(25%)

Phase Distribution

Ph phase_1
2
50%
Ph phase_3
2
50%

Phase Distribution

2

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 3Large-scale testing
2(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

3

trials recruiting

Total Trials

4

all time

Status Distribution
Active(3)
Terminated(1)

Detailed Status

Recruiting2
Terminated1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
3
Success Rate
0.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (50.0%)
Phase 32 (50.0%)

Trials by Status

recruiting250%
terminated125%
active_not_recruiting125%

Recent Activity

3 active trials
Showing 4 of 4
active_not_recruitingphase_3

Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome

NCT05457556
recruitingphase_1

A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant

NCT07020533
recruitingphase_1

Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma

NCT05432635
terminatedphase_3

Dose-reduced Versus Standard Conditioning in MDS/sAML

NCT01203228

Clinical Trials (4)

Showing 4 of 4 trials
NCT05457556Phase 3

Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome

Active Not Recruiting
NCT07020533Phase 1

A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant

Recruiting
NCT05432635Phase 1

Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma

Recruiting
NCT01203228Phase 3

Dose-reduced Versus Standard Conditioning in MDS/sAML

Terminated

All 4 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
4